Citations

Clear

2303 citation(s) found for "Yu, Edward".

Letter: Pressure to Publish—A Precarious Precedent Among Medical Students
Jarvis, Nicholas R. , Quiñones‐Hinojosa, Alfredo , Redett, Richard J. , Reece, Edward M., Noland, Shelley S. , Singh, Rohin

Mayo Clinic

Neurosurgery | October 11, 2022 | Volume: 91 | Issue: 6 | Pages: e172-e173

10.1227/neu.0000000000002176 | PMID 36218366 Get It

Results of the North American Complex Abdominal Aortic Debranching (NACAAD) Registry
Escobar, Guillermo A. , Oderich, Gustavo S. , Souza, Leonardo Reis de, Quiñones‐Baldrich, William J., Patel, Himanshu J. , Eliason, Jonathan L. , Timaran, Carlos H. , Black, James H. , Ellozy, Sharif H. , Woo, Edward Y., Fillinger, Mark F., Singh, Michael J. , Lee, Jason T. , Lall, Purandath , Gloviczki, Péter , Kalra, Manju , Duncan, Audra A. , Lyden, Sean P. , Tenorio, Emanuel R. , Investigators, for the NACAAD, Patel, Himanshu J , H Timaran, Carlos , Tenorio, Emanuel R , Oderich, Gustavo S , Farber, Mark , Upchurch, Gilbert R. , Jiménez, Juan Carlos , Investigators, for the NACAAD, Gloviczki, Péter

Mayo Clinic

Circulation | October 10, 2022 | Volume: 146 | Issue: 15 | Pages: 1149-1158

10.1161/circulationaha.120.045894 | PMID 36148651 Get It

Background: Hybrid debranching repair of pararenal and thoracoabdominal aortic aneurysms was initially designed as a better alternative to standard open repair, addressing the limitations of endovascular repair involving the visceral aorta. We reviewed the collective outcomes of hybrid debranching repairs using extra-anatomic, open surgical debranching of the renal-mesenteric arteries, followed by endovascular aortic stenting. Methods: Data from patients who underwent hybrid repair in 14 North American institutions during 10 years were retrospectively reviewed. Society of Vascular Surgery scores were used to assess comorbidity risk. Early and late outcomes, including mortality, morbidity, reintervention, and patency were analyzed. Results: A total of 208 patients (118 male; mean age, 71±8 years old) were treated by hybrid repair with extraanatomic reconstruction of 657 renal and mesenteric arteries (mean 3.2 vessels/patient). Mean aneurysm diameter was 6.6±1.3 cm. Thoracoabdominal aortic aneurysms were identified in 163 (78%) patients and pararenal aneurysms in 45 (22%). A single-stage repair was performed in 92 (44%) patients. The iliac arteries were the most common source of inflow (n=132; 63%), and most (n=150; 72%) had 3 or more bypasses. There were 30 (14%) early deaths, ranging widely across sites (0%–21%). A Society of Vascular Surgery comorbidity score >15 was the primary predictor of early mortality ( P <0.01), whereas mortality was 3% in a score ≤9. Early complications occurred in 140 (73%) patients and included respiratory complications in 45 patients (22%) and spinal cord ischemia in 22 (11%), of whom 10 (45%) fully recovered. At 5 years, survival was 61±5%, primary graft patency was 90±2%, and secondary patency was 93±2%. The most significant predictor of late mortality was renal insufficiency ( P <0.0001). Conclusions: Mortality after hybrid repair and visceral debranching is highly variable by center, but strongly affected by preoperative comorbidities and the centers’ experience with the technique. With excellent graft patency at 5 years, the outcomes of hybrid repair done at centers of excellence and in carefully selected patients may be comparable (or better) than traditional open or even totally endovascular approaches. However, in patients already considered as high-risk for surgery, it may not offer better outcomes.
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
DeVries, Amber A , Peng, Pei-Chen , Reyes, Alberto Luiz P., Plummer, Jasmine , Davis, Brian , Chen, Stephanie S., Dezem, Felipe Segato , Antonenkova, Natalia, Beckmann, Matthias W. , Beeghly‐Fadiel, Alicia, Bogdanova, Natalia , Bogdanova-Markov, Nadja, Brenton, James D. , Chang‐Claude, Jenny , Dörk, Thilo , Eccles, Diana M, Fasching, Peter A. , Goode, Ellen L. , Goodman, Marc T. , Group, OPAL Study, Grant, Peter , Nagle, C.A., Chevenix-Trench, G, Bowtell, D, Blomfield, Penny, Davis, Alison , Leung, Yee , Livingstone, Karen, O’Neill, Helen C. , Black, Amanda , Hadley, Alison , Shannon, Colleen, Neesham, Deborah, Otton, Geoffrey, Au‐Yeung, George , Goss, Geraldine , Wain, Gerard, Gard, Grace , Robertson, G S M, Lombard, Janine , Tan, Joanne , McNeilage, Jane, Power, J. , Miller, Jessica A., Lamont, John, Wong, Kit Man , Reid, Kate , Milishkin, L, Buck, Martin , Bunting, Michael W, McNally, Orla , Awad, Reda, Mohan, Rahul , Farrell, Rhonda , McIntosh, Rachel, Rome, Robert, Houghton, R., Hogg, Russell , Land, R., Baron‐Hay, Sally , Paramasivum, S, Pather, Selvan , Hyde, Samuel M. , Salfinger, Stuart , Valmadre, Susan, Jobling, Thomas W., Manolitsas, Tom, Bonaventura, T, Group, AOCS, Bowtell, D, Green, A, Webb, P, Gertig, DM, Moore, S., Hung, Jillian A., Harrap, Karen L. , Sadkowsky, T., Malt, M. , Robertson, R. Paul , Bergh, T. Vanden, Jones, Michelle R. , Nattress, K., Chiew, Yoke-Eng, Stenlake, Annie, Ashover, P., Corrish, T., Jackman, Louisa, Ferguson, Kaltin , Martin, Kara, Martyn, Amanda C. , White, Jonathan, Jayde, V., Bowes, Laura, Mamers, Pamela, Galletta, Laura, Giles, Daniel A., Hendley, Joy , Shirley, H., Ball, C., Young, Christian D. , Viduka, S., Bilic, Sanela , Glavinas, Lydia, Brooks, Jacqueline D., Stuart‐Harris, R., Kirsten, Fred, Rutovitz, J , Clingan, P., Proietto, Anthony , Braye, Stephen, Shannon, J., Bonaventura, T, Begbie, Stephen , Hildebrandt, Michelle A.T., Huff, Chad D. , Huntsman, David G., Kar, Siddhartha , Labrie, Marilyne , Lambrechts, Diether , Le, Nhu D. , May, Taymaa, Menon, Usha , Moysich, Kirsten B. , Odunsi, Kunle , Olsson, Håkan , Pearce, Celeste Leigh , Ramus, Susan J. , Ríboli, Elio , Riggan, Marjorie J. , Romieu, Isabelle , Schildkraut, Joellen M. , Sieh, Weiva , Song, Honglin , Sutphen, Rebecca , Terry, Kathryn L. , Thompson, Pamela J., Titus, Linda , Tworoger, Shelley S. , Nieuwenhuysen, Els Van , Edwards, Digna Velez, Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Freedman, Matthew L., Lawrenson, Kate , Easton, Douglas F. , Gayther, Simon A. , Eccles, Diana , Bowtell, David D.L. , Lambrechts, Diether , Dennis, Joe , Plummer, Jasmine T , Anton-Culver, Hoda , Campbell, Ian G , Chenevix-Trench, Georgia , Eliassen, A Heather , Jensen, Allan , Kar, Siddhartha , Menon, Usha , Riboli, Elio , Sieh, Weiva , Webb, Penelope M , Wentzensen, Nicolas , Wolk, Alicja , Ziogas, Argyrios , Lawrenson, Kate , Jones, Michelle R , Dörk, Thilo , Lambrechts, Diether , Ramus, Susan J , Tworoger, Shelley S , Eccles, Diana , Brenton, James D , Moysich, Kirsten , Lambrechts, Diether , Bogdanova, Natalia V , Bowtell, David D , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Aben, Katja K.H. , Anton‐Culver, Hoda , Beeghly‐Fadiel, Alicia , Berchuck, Andrew , Bützow, Ralf C. , Campbell, Ian , Chenevix‐Trench, Georgia , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Eliassen, A. Heather , Fortner, Renée T. , Giles, Graham G. , Gronwald, Jacek , Group, OPAL Study, Friedländer, Michael , Obermair, Andreas , Nagle, C, Beesley, Vanessa L. , Bowtell, D, Brand, Alison H. , Nicklin, James , Quinn, Michael A. , Williams, M, Hadley, A, Glasgow, A, Garrett, A, Rao, A, Steer, Christopher , Allen, Deborah Emma , Robertson, G, Power, J, Coward, Jermaine , Carter, Jonathan , Lamont, J, Wong, K M, Perrin, Lewis C , Nascimento, M, Buck, M, Harrison, Michelle , Chetty, Naven , Hacker, Neville F. , Harnett, Paul R. , Beale, Philip James , Awad, R, McIntosh, R, Sayer, R, Hogg, R, Hyde, S, Bonaventura, T, Arora, Vivek , Group, AOCS, Bowtell, D, Webb, P, Gertig, Dorota M., Traficante, Nadia , Fereday, Sián , Pandeya, Nirmala , Robertson, R, McKenzie, P, Maidens, J, Sullivan, Helen T. , Alexander, Brian M. , Brown, S, Green, L, Jackman, L, Martyn, A, Ranieri, B, White, J, Giles, D, Alsop, Kathryn , Schmidt, T, Young, C, Tran, H, Rutovitz, J, Glasgow, A, Shannon, J, Bonaventura, T, Stewart, James , Håkansson, Niclas , Hildebrandt, Michelle A.T. , Jensen, Allan , Karlan, Beth Y. , Хуснутдинова, Э. К. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Kupryjańczyk, Jolanta , Lubiński, Jan , Milne, Roger L. , Modugno, Francesmary , Monteiro, Álvaro N.A. , Pejovic, Tanja B. , Sandler, Dale P. , Setiawan, Veronica Wendy , Edwards, Digna R. Velez , Webb, Penelope M. , Wolk, Alicja , Ziogas, Argyrios , Pharoah, Paul D.P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 10, 2022 | Volume: 114 | Issue: 11 | Pages: 1533-1544

10.1093/jnci/djac160 | PMID 36210504 Get It

AbstractBackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingle nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer–related cell types.ResultsWe identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P &lt; .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P &lt; .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types.ConclusionsCNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Johnson, Amanda M. , Barsky, Maria, Ahmed, Waseem , Zullow, Samantha, Galati, Jonathan S. , Jairath, Vipul , Narula, Neeraj , Peerani, Farhad , Click, Benjamin , Coburn, Elliot, Dang, ThucNhi T. , Garg, Rajat , Aggarwal, Manik , Mohammad, Danah, Halloran, Brendan P. , Kochhar, Gursimran , Todorowski, Hannah, Din, Nabeeha Mohy Ud, Izanec, James , Teeple, Amanda, Gasink, C, Muser, Erik, Ding, Zhijie , Lakhani, Komal, Hogan, Dan, Datta, Samit, Boland, Brigid S. , Bohm, Matthew , Fischer, Monika , Sagi, Sashidhar , Afzali, Anita , Ullman, Thomas, Lawlor, Garrett , Baumgart, Daniel C. , Chang, Shannon, Scherl, Ellen , Sandborn, William J. , Bruining, David H. , Kane, Sunanda V. , Loftus, Edward V. , Dulai, Parambir S. , Jairath, Vipul , Jairath, Vipul , Bruining, David, Jairath, V , Jairath, V , Loftus, Edward V , Jairath, Vipul , Gold, Stephanie Lauren , Agrawal, Manasi , Swaminath, Arun C. , Hogan, Dan, Ungaro, Ryan C. , Chang, Shannon, Hudesman, David , Lukin, Dana J. , Colombel, Jean‐Frédéric , Sands, Bruce E , Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

American Journal of Gastroenterology | October 3, 2022 | Volume: 118 | Issue: 2 | Pages: 317-328

10.14309/ajg.0000000000002047 | PMID 36191274 Get It

INTRODUCTION: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). METHODS: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients. Data included patient demographics, disease phenotype, disease activity, treatment history, and concomitant medications. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions were assessed using time-to-event analysis, and clinical predictors were assessed by using multivariate Cox proportional hazard analyses. Serious infections and adverse events were defined as those requiring hospitalization or treatment discontinuation. RESULTS: A total of 1,113 patients (51.8% female, 90% prior antitumor necrosis factor exposure) were included, with a median follow-up of 386 days. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions at 12 months were 40%, 32%, 39%, and 30%, respectively. Biologic-naive patients achieved significantly higher rates of clinical and endoscopic remissions at 63% and 55%, respectively. On multivariable analyses, prior antitumor necrosis factor (hazard ratio, 0.72; 95% confidence interval, 0.49–0.99) and vedolizumab exposure (hazard ratio, 0.65; 95% confidence interval, 0.48–0.88) were independently associated with lower likelihoods of achieving endoscopic remission. In patients who experienced loss of remission, 77 of 102 (75%) underwent dose optimization, and 44 of 77 (57%) achieved clinical response. An additional 152 of 681 patients (22.3%) were dose-optimized because of primary nonresponse incomplete response to UST, of whom 40.1% (61 of 152) responded. Serious infections occurred in 3.4% of patients while other noninfectious adverse events (lymphoma [n = 1], arthralgia [n = 6], rash [n = 6], headache [n = 3], hepatitis [n = 3], hair loss [n = 3], neuropathy [n = 1], and vasculitis [n = 1]) occurred in 2.4% of patients. DISCUSSION: UST represents a safe and effective treatment option for CD, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months. The greatest treatment effect of UST was seen in biologic-naive patients, and dose escalation may recapture clinical response.
Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H-Specific Human Cellular and Zebrafish Models
Wentworth, Kelly L. , Lalonde, Robert L. , Groppe, Jay C. , Brewer, Niambi , Moody, Tania , Hansberry, Steven , Taylor, Kimberly E. , Shore, Eileen M. , Pignolo, Robert J. , Yelick, Pamela C. , Pignolo, Robert J , Hsiao, Edward C , Shore, Eileen M , Kaplan, Frederick S. , Hsiao, Edward C.

Mayo Clinic

Journal of Bone and Mineral Research | September 25, 2022 | Volume: 37 | Issue: 11 | Pages: 2058-2076

10.1002/jbmr.4711 | PMID 36153796 Get It

ABSTRACT Bone morphogenetic protein (BMP) signaling is critical in skeletal development. Overactivation can trigger heterotopic ossification (HO) as in fibrodysplasia ossificans progressiva (FOP), a rare, progressive disease of massive HO formation. A small subset of FOP patients harboring the causative ACVR1R206H mutation show strikingly mild or delayed-onset HO, suggesting that genetic variants in the BMP pathway could act as disease modifiers. Whole-exome sequencing of one such patient identified BMPR1AR443C and ACVR2AV173I as candidate modifiers. Molecular modeling predicted significant structural perturbations. Neither variant decreased BMP signaling in ACVR1R206H HEK 293T cells at baseline or after stimulation with BMP4 or activin A (AA), ligands that activate ACVR1R206H signaling. Overexpression of BMPR1AR443C in a Tg(ACVR1-R206Ha) embryonic zebrafish model, in which overactive BMP signaling yields ventralized embryos, did not alter ventralization severity, while ACVR2AV173I exacerbated ventralization. Co-expression of both variants did not affect dorsoventral patterning. In contrast, BMPR1A knockdown in ACVR1R206H HEK cells decreased ligand-stimulated BMP signaling but did not affect dorsoventral patterning in Tg(ACVR1-R206Ha) zebrafish. ACVR2A knockdown decreased only AA-stimulated signaling in ACVR1R206H HEK cells and had no effect in Tg(ACVR1-R206Ha) zebrafish. Co-knockdown in ACVR1R206H HEK cells decreased basal and ligand-stimulated signaling, and co-knockdown/knockout (bmpr1aa/ab; acvr2aa/ab) decreased Tg(ACVR1-R206Ha) zebrafish ventralization phenotypes. Our functional studies showed that knockdown of wild-type BMPR1A and ACVR2A could attenuate ACVR1R206H signaling, particularly in response to AA, and that ACVR2AV173I unexpectedly increased ACVR1R206H-mediated signaling in zebrafish. These studies describe a useful strategy and platform for functionally interrogating potential genes and genetic variants that may impact the BMP signaling pathway. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes
Bakhshi, Zeinab , Yadav, Siddhant, Harmsen, William S. , Varayil, Jithinraj Edakkanambeth , Karls, Kevin A, Tremaine, William J., Loftus, Edward V. , Edakkanambeth Varayil, Jithinraj, Loftus, Edward V , Edakkanambeth Varayil, Jithinraj , Karls, Kevin A.

Mayo Clinic

Inflammatory Bowel Diseases | September 23, 2022 | Volume: 29 | Issue: 8 | Pages: 1223-1230

10.1093/ibd/izac198 | PMID 36149260 Get It

AbstractBackgroundAvascular necrosis (AVN) is a known adverse event associated with corticosteroid (CS) usage. Inflammatory bowel disease (IBD) is often treated with a CS for induction of remission. We sought to describe clinical features and outcomes of IBD patients with AVN.MethodsIn this retrospective, single-center, case-control study, patients with IBD who had a diagnosis of osteonecrosis, aseptic necrosis, or AVN from 1976 to 2009 were included, and each was matched with up to 2 controls (IBD but no AVN) on age, sex, IBD subtype, geographic area of residence, and date of IBD diagnosis. We abstracted risk factor data from the medical records. Conditional logistic regression was performed accounting for minor differences in age and date of first IBD visit to assess the relationship between putative risk factors and AVN, expressed as odds ratio and 95% confidence interval.ResultsEighty-five patients were diagnosed with IBD-AVN and were matched with 163 controls. The mean age at AVN diagnosis was 47.5 years. AVN was diagnosed a median of 12.2 years after IBD diagnosis, and the control group was followed for a median of 15 years after IBD diagnosis to ensure that they did not have AVN. Ten percent of patients with AVN did not have any CS exposure. History of arthropathy or estrogen use in Crohn’s disease and use of CS, osteoporosis, and history of arthropathy in ulcerative colitis were significantly associated with AVN.ConclusionsMost patients with IBD-AVN had multifocal involvement. Most had received CS, but many patients had other risk factors including arthropathy.
Detectability of Small Low-Attenuation Lesions With Deep Learning CT Image Reconstruction: A 24-Reader Phantom Study
Toia, Giuseppe V. , Zamora, D , Singleton, Michael, Shuman, William P. , Kanal, Kalpana M. , Mileto, Achille , Singleton, Michael, Liu, Arthur , Tan, Edward, Leng, Shuai

Mayo Clinic

American Journal of Roentgenology | September 21, 2022 | Volume: 220 | Issue: 2 | Pages: 283-295

10.2214/ajr.22.28407 | PMID 36129222 Get It

Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy
Morris, Alan H. , Horvat, Christopher M. , Grainger, David W. , Orme, James F., Clemmer, Terry P., Weaver, Lindell K., Thomas, Frank O, Grissom, Colin K. , Hirshberg, Ellie , East, Thomas D. , Wallace, C. Jane, Young, Michael , Sittig, Dean F. , Pearl, James E., Pesenti, Antinio, Bombino, Michela, Beck, Eduardo, Sward, Katherine , Phansalkar, Shobha, Bernard, Gordon R. , Brower, Roy G., Truwit, Jonathon D. , Steingrub, Jay S. , Hiten, R Duncan, Willson, Douglas F., Randolph, Adrienne G. , Curley, Martha A. Q. , Newth, Christopher J. L. , Lacroix, Jacques, Agus, Michael S. D. , Lee, Kang Hoe, deBoisblanc, Bennett P., Moore, Frederick A. , Evans, R. Scott, Sorenson, Dean, Wong, Anthony, Boland, Michael V. , Dere, W. , Crandall, Alan S. , Huff, Stanley M. , Haug, Peter J. , Pielmeier, Ulrike , Rees, Stephen Edward , Karbing, Dan Stieper , Berger, Kenneth I. , Oppenheimer, Beno W. , Pickering, Brian W. , Schoenfeld, David , Tocino, Irena , Savitz, Lucy A., Dreyfuss, Didier, Slutsky, Arthur S. , Crapo, James D. , Pinsky, Michael R. , James, Brent C., Berwick, Donald M. , Sittig, Dean F , Sward, Katherine A , Weir, Charlene , Huff, Stanley M , Gonnering, Russell S , Randolph, Adrienne G , Stagg, Brian C. , Lanspa, Michael J. , Suchyta, Mary R. , Thompson, Bruce , Zimmerman, Jerry J. , Nadkarni, Vinay , Facelli, Julio Cesar , Andreassen, Steen , Fan, Eddy , Goldring, Roberta M. , Ely, Eugene Wesley , Pronovost, Peter J.

Mayo Clinic

Journal of the American Medical Informatics Association | September 20, 2022 | Volume: 30 | Issue: 1 | Pages: 178-194

10.1093/jamia/ocac143 | PMID 36125018 Get It

AbstractHow to deliver best care in various clinical settings remains a vexing problem. All pertinent healthcare-related questions have not, cannot, and will not be addressable with costly time- and resource-consuming controlled clinical trials. At present, evidence-based guidelines can address only a small fraction of the types of care that clinicians deliver. Furthermore, underserved areas rarely can access state-of-the-art evidence-based guidelines in real-time, and often lack the wherewithal to implement advanced guidelines. Care providers in such settings frequently do not have sufficient training to undertake advanced guideline implementation. Nevertheless, in advanced modern healthcare delivery environments, use of eActions (validated clinical decision support systems) could help overcome the cognitive limitations of overburdened clinicians. Widespread use of eActions will require surmounting current healthcare technical and cultural barriers and installing clinical evidence/data curation systems. The authors expect that increased numbers of evidence-based guidelines will result from future comparative effectiveness clinical research carried out during routine healthcare delivery within learning healthcare systems.
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
Ferrante, Marc , Feagan, Brian G. , Hibi∥, Toshifumi , Sandborn, William J. , Ritter, Timothy E., Loftus, Edward V. , Rogler, Gerhard , Oortwijn, Alessandra , Yun, Chohee , Brun, Franck‐Olivier Le , Dinoso, Jason B., Hsieh, Jeremy, Vermeire, Séverine , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Schreiber, Stefan

Mayo Clinic

American Journal of Gastroenterology | September 16, 2022 | Volume: 118 | Issue: 1 | Pages: 138-147

10.14309/ajg.0000000000001979 | PMID 36113491 Get It

INTRODUCTION: Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and sustainability of response to filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, in adults with moderately to severely active UC in the phase 2b/3 SELECTION trial. The association between early symptomatic improvements and health-related quality of life (HRQoL) outcomes was also assessed. METHODS: In these post hoc analyses of the double-blinded, randomized, placebo-controlled 58-week SELECTION trial (NCT02914522), rectal bleeding and stool frequency diary data on days 1–15 and pMCS remission and response at multiple time points including weeks 10 and 58 were evaluated. HRQoL was assessed using the Inflammatory Bowel Disease Questionnaire at weeks 10 and 58. RESULTS: Filgotinib 200 mg relative to placebo improved rectal bleeding and stool frequency within 7 days ( P < 0.05). By week 2, greater proportions of filgotinib 200 mg-treated patients than placebo-treated patients achieved pMCS remission (biologic-naive, 15.1% vs 8.0%, P = 0.0410; biologic-experienced, 10.3% vs 4.2%, P = 0.0274). A similar treatment effect was observed at week 58 ( P < 0.0001). Day 7 rectal bleeding and stool frequency subscores were associated with the Mayo Clinic Score response at weeks 10 and 58. Patients in pMCS remission at weeks 10 and 58 had greater improvements in the Inflammatory Bowel Disease Questionnaire score than those not in pMCS remission. DISCUSSION: Filgotinib 200 mg daily resulted in rapid and sustained improvements in both UC symptoms and HRQoL.
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
Esplin, Edward D. , Nielsen, Sarah M. , Bristow, Sara L. , Garber, Judy E. , Hampel, Heather , Rana, Huma Q. , Samadder, N. Jewel , Shore, Neal D. , Nussbaum, Robert L. , Nussbaum, Robert , Garber, J. E. , Hampel, Heather , Esplin, Edward D , Rana, Huma Q , Shore, Neal

Mayo Clinic

JCO Precision Oncology | September 15, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00516 | PMID 36108258 Get It